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Background: MicroRNAs (miRNAs) are important post-transcriptional regulators that have been demonstrated to
play an important role in human diseases. Elucidating the associations between miRNAs and diseases at the
systematic level will deepen our understanding of the molecular mechanisms of diseases. However, miRNA-disease
associations identified by previous computational methods are far from completeness and more effort is needed.
Results: We developed a computational framework to identify miRNA-disease associations by performing random
walk analysis, and focused on the functional link between miRNA targets and disease genes in protein-protein
interaction (PPI) networks. Furthermore, a bipartite miRNA-disease network was constructed, from which several
miRNA-disease co-regulated modules were identified by hierarchical clustering analysis. Our approach achieved
satisfactory performance in identifying known cancer-related miRNAs for nine human cancers with an area under
the ROC curve (AUC) ranging from 71.3% to 91.3%. By systematically analyzing the global properties of the
miRNA-disease network, we found that only a small number of miRNAs regulated genes involved in various
diseases, genes associated with neurological diseases were preferentially regulated by miRNAs and some
immunological diseases were associated with several specific miRNAs. We also observed that most diseases in the
same co-regulated module tended to belong to the same disease category, indicating that these diseases might
share similar miRNA regulatory mechanisms.
Conclusions: In this study, we present a computational framework to identify miRNA-disease associations, and
further construct a bipartite miRNA-disease network for systematically analyzing the global properties of miRNA
regulation of disease genes. Our findings provide a broad perspective on the relationships between miRNAs and
diseases and could potentially aid future research efforts concerning miRNA involvement in disease pathogenesis.
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MicroRNAs (MiRNAs) are important regulators that
can strongly affect cellular functions including pro-
liferation, differentiation, and apoptosis through post-
transcriptional negative regulation of target gene expression
[1]. Dysregulated expression of miRNAs has been pre-
viously demonstrated in human diseases, and there is a
growing body of evidence regarding the important
roles of miRNAs in human diseases [2]. Identification
of disease-related miRNAs will aid in the pathological
classification of diseases and help to formulate indi-
vidualized treatment regimes [3].
Thus far, computational prediction methods for miRNA-
disease associations have produced some valuable results.
Under the assumption that functionally related miRNAs
tend to be associated with phenotypically similar diseases
[4], Jiang et al. [5] used a hypergeometric distribution to
construct a miRNA functional network and used phe-
notype similarity information to infer potential miRNA-
disease associations. The hypergeometric distribution
method considers the number of overlapping genes
while neglecting the functional link between them, and
the scoring system used in their study only considered
the direct neighbour information of each miRNA in
the miRNA functional network. Chen et al. [6] assessed
potential miRNA-disease interactions through a miRNA-
miRNA functional similarity network that was constructed
based on the similarity of miRNA-associated diseases.
However, this method is not applicable to diseases that
have no known related miRNAs.
MiRNA mainly performs its regulatory function through
its targets, and thus we presumed that if targets of a
miRNA correlate with disease genes then the miRNA
tends to be associated with the disease. Functional con-
nections between miRNA targets and disease genes
could be obtained via PPI network. Functional PPI net-
works include information on physical interactions,
functional communication, and associations between
the expression levels of genes, and they serve as an im-
portant foundation for understanding the functional
roles of biomolecules [7,8]. In addition, random walk
analysis is a global network distance measurement that is
usually used to measure similarities between the nodes of
a network, and previous reports have demonstrated its ef-
fectiveness in candidate disease gene prioritization [9,10].
Random walk analysis has been shown to outperform
many existing local network-based gene prioritization
algorithms [9,10]. Therefore, we proposed a new algorithm
for identifying miRNA-disease associations.
Additionally, dissection of miRNA-disease networks can
reveal regulatory mechanisms of human diseases from
different perspectives. Currently, a miRNA-disease net-
work can be constructed primarily using three different
methods. The first method is based on published reportmining. For example, Lu et al. [4] built a human miRNA-
disease bipartite network by manually collecting miRNA-
disease association data from publications. This method
generally includes only a few types of interactions, thus
causing a lack of systematization [11]. The second ap-
proach involves applying unbiased high-throughput exper-
iments to the whole miRNAome. Although current
technological progress suggests that comprehensive
human biological network maps will be completed in the
next few years, this method remains difficult to initiate
[12]. The third method involves computational prediction
that can quickly and effectively predict miRNA-disease
associations to construct a miRNA-disease network. Such
a network generally contains large numbers of nodes and
edges to meet the needs of systematic analysis.
In this study, we developed a computational frame-
work to identify potential miRNA-disease associations
by taking advantage of the functional connections between
miRNA targets and disease genes in protein-protein inter-
action (PPI) networks. The predicted miRNA-disease
associations were provided to identify novel miRNAs with
aberrant expression in human diseases. Furthermore, we
constructed a miRNA-disease network and analyzed its fea-
tures, and found that some miRNAs combined to regulate
disease-related genes in the same disease class.
Methods
Human protein-protein interaction (PPI) data and random
PPI networks
The PPI data for human was compiled from the Human
Protein Reference Database (HPRD Release 9) containing
annotations pertaining to human proteins based on ex-
perimental evidence from published reports [13]. The en-
tire network contained 9453 genes and 36867 interactions.
We mapped gene names to Entrez gene IDs and then
obtained the maximum components of the whole net-
work, which contains 9028 genes and 35865 interactions.
It is noteworthy that PPI data in HPRD were annotated as
common to all protein isoforms, primarily because of the
general lack of experimental data [13]. A total of 1,000
random PPI networks were acquired by randomly shuf-
fling the above PPI network while maintaining the degree
of each node unchanged.
Disease genes and miRNA targets
The disease-gene association data were obtained from a
study by Li [14], which contained 15149 relationships in-
volving 412 diseases and 2831 disease genes that belong to
18 disease classes. MiRNA target genes were acquired
from seven miRNA target databases: miRanda [15], PicTar
[16], TargetScan [17], DIANA-microT [18], RNA22 [19],
RNAhybrid [20], and miRBase Targets [21]. We extracted
the regulatory associations between miRNAs and targets,
which appeared in at least three databases in order to
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52828 targeting pairs that involved 566 miRNAs and 8085
target genes. This method has also been adopted in a pre-
vious study [22]. After the above disease genes and
miRNA targets were annotated to the HPRD network, 269
diseases and 499 miRNAs with target genes more than five
were remained, including 2160 disease genes.
Identification of miRNA-disease pairs and construction of
a miRNA-disease network
MiRNA mainly performs its regulatory function through
its targets. We thus presumed that if targets of a
miRNA are correlated with disease genes, the miRNA
tends to be associated with the disease. Based on this
hypothesis, we used a framework to identify miRNA-
disease associations and further constructed a miRNA-
disease network.Figure 1 An overview of the construction of the miRNA-disease netw
analysis using the disease genes as seeds and the miRNA targets as seeds
to measure the potential regulatory relationship between the miRNA and d
pair and further adopted all of the significant miRNA-disease pairs to constThe strategy to identify miRNA-disease pairs using
our model is shown in Figure 1. For a miRNA-disease
pair, firstly, we mapped the causal genes of the disease
and the miRNA target genes onto the PPI network.
Then, we obtained a gene rank list using the random
walk with restart (RWR) algorithm (see Additional file 1)
with the disease genes serving as seeds. Every miRNA
target gene was given a probability value in the above
ranked gene list. The larger the probability value, the
more similar the miRNA target gene was to the known
disease gene. The miRNA targets that ranked at the top
of the list should exhibit a stronger association with the
disease, because these targets have a higher similarity to
disease genes compared with those ranked at the bottom
of the list. The ranked gene list used in this study was
obtained using the RWR algorithm with disease genes as
seeds, derived from gene set enrichment analysis (GSEA)ork. Step 1: For a given miRNA and disease, we used random walk
simultaneously to obtain the ES. Step 2: Computation of p-value, used
isease. Step 3: We repeated step 1 and step 2 for any disease-miRNA
ruct a miRNA-disease network.
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where TG ¼ g1; g2;…; gn1
 
denotes the miRNA target
gene set including n1 genes. The gene rank list L = {g1, g2,…,
gN} obtained included N genes, where N represents the
number of genes involved in the PPI network. The miRNA
targets TG ¼ g1; g2;…; gn1
 
were ranked in this gene list.
Subsequently, we calculated a running sum statistic. Begin-
ning with the top-ranking gene, the running sum was calcu-










if the gene is not in TG.
ES1 is defined as the greatest positive deviation of the run-
ning sum across all N genes. Similarly, for the same
miRNA-disease pair referred to above, we computed ES2 by



















where DG ¼ g1; g2;…; gn2
 
denotes the disease gene
set including n2 disease genes. Following the above pro-
cedure for the same miRNA-disease pair, we computed
ES1 and ES2 using the RWR algorithm with disease
genes as seeds and miRNA target genes as seeds, re-
spectively. We then computed their combination as ES
with the following formula:
ES ¼ βES1 þ 1−βð ÞES2 ð3Þ
The parameter β ∈ (0, 1) is used to control the effect of
two kinds of seed nodes, disease genes and miRNA tar-
gets. If β is 0.5, the seed nodes of disease genes and
miRNA targets are weighted equally. If β is above 0.5,
the seed nodes of disease genes are given more import-
ance. In this study, we set β as 0.5.
Secondly, we used a p-value to measure the signifi-
cance of the association between the miRNA and the
disease. The p-value was defined as the fraction of ran-
domly achieved ESs greater than or equal to the true ES.
As stringent controls, 1000 random networks were cons-
tructed by preserving the number of direct neighbors for
each protein in the original PPI network using the edge
switching method [22,24-26]. This procedure enabled us
to obtain 1,000 ESs while maintaining the networkstructure. The p-value was computed using the formula
below:
p‐value disease;miRð Þ ¼ k=1000 ð4Þ
where k is the number of ESs computed by random PPI
networks greater than or equal to the ES computed by
the true PPI network. The p-value (disease, miR) reflects
the correlation between the miRNA and the disease. The
lower the p-value (disease, miR), the greater the prob-
ability that the miRNA is associated with the develop-
ment, diagnosis, and prognosis of the disease.
Finally, we computed p-values for disease-miRNA pairs
between 269 diseases and 499 miRNAs by applying the
procedures described above. We set up a p-value thresh-
old (e.g., 0.05) to determine whether a miRNA and a dis-
ease had a link. MiRNA and disease pairs with p-values
less than the threshold will be connected by a direct link.
Otherwise, they are not connected directly. Thus, a
miRNA-disease network can be constructed using this
approach. It is worth noting that for each disease, different
p-value thresholds only affect the number of miRNA-
disease associations, but not the rank of the miRNAs.
Results
Stable performance of our algorithm
To evaluate the performance of our algorithm in identi-
fying miRNA-disease associations, we performed a valid-
ation on nine human cancers. The testing set for the
performance of our method was selected as follows. For
each cancer, the known cancer related miRNAs were
obtained from miR2Disease [27] and HMDD [4] databases
that provide a comprehensive record of miRNA deregula-
tion involved in human diseases. We extracted the
miRNA-cancer associations yielded by low-throughput
methods such as northern blot and quantitative RT–PCR
approaches as positive samples. In total, we obtained 518
known miRNA-cancer associations. The number of
miRNAs associated with each cancer was different, ran-
ging from nine to 104 (Additional file 1: Table S1).
At present, collecting non-cancer related miRNA is dif-
ficult or even impossible. In this study, we chose
miRNAs that exhibited the lowest fold change values as
negative controls by analyzing the corresponding
expression profile of the respective cancer. We also
used the same number of negative controls as that of
positive samples (Additional file 1: Table S1). MiRNA ex-
pression profiles of nine human cancers were downloaded
from the Gene Expression Omnibus (GEO) and The
Cancer Genome Atlas (TCGA) (for a detailed description,
see Additional file 1). We scored miRNAs for each of the
nine cancers according to our method. The score was
then compared with a specified threshold δ with lower
thresholds yielding more conservative predictions. True
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known disease miRNAs below the threshold whereas
false positives (FP) are associations that satisfy the
p-value (disease, miR) ≤ δ but are not confirmed by
current knowledge. True negatives (TN) are miRNA-
disease associations that satisfy the p-value (disease,
miR) ≤ δ for which the miRNAs are not currently
known to be associated with the disease, whereas false
negatives (FN) are miRNA-disease associations that cor-
respond to known disease miRNAs but are above the
threshold. The sensitivity is TP/(TP + FN), and the spe-
cificity is TN/(TN + FP). The ROC curve was plotted by
computing the sensitivity and specificity while varying
the threshold. At the same time, we calculated the cor-
responding area under the ROC curve (AUC) values for
each cancer. The results are shown in Additional file 1:
Table S2. AUC values ranged from 71.3 to 91.3% in all
nine cancers, and the AUC values of three cancers
exceeded 0.8. In addition, we computed the AUC value for
all of the known 518 miRNA-cancer pairs together to
evaluate the method, and we obtained an AUC value of
76.7%. These results indicated that our algorithm was ef-
fective for identification of miRNA-disease associations.
To evaluate the robustness of our method, we con-
sidered different networks, disease-related genes, and
parameters. Signaling networks are a critical cell commu-
nication platform for disease development, In particular,
strong evidence shows that cancer is a disease with abnor-
mal cell signaling [28]. We implemented our method in a
human signaling network that contains ~6,300 proteins
and ~63,000 signaling relations [29-32]. As a result, the
AUC values of nine cancers were comparable with that
of the PPI network (Additional file 1: Table S3).
Disease-related genes identified by DNA sequencing
technology were also used to evaluate the robustness
of our algorithm. Because of the lack of data, we
assessed four kinds of cancer-related genes from pub-
lished reports (breast cancer [33], glioma [34], ovarian
cancer [35], and sarcoma [36]). The results showed
that the AUC values of four cancers were slightly
lower than that we obtained previously (Additional file
1: Table S4). In the first step of our algorithm, there is
one parameter β, to investigate the stability of the
algorithm, and we applied it to nine human cancers
with a β range of 0.1 to 0.9 in increments of 0.1. The
results are shown in Additional file 1: Table S5 and
Figure S1. For each cancer, the AUC values did not
change significantly as β varied. We also evaluated the ef-
fect of the restart probability α in the RWR algorithm. We
set various values of α ranging from 0.1 to 0.9 with a step
of 0.2. The AUC values for each cancer were calculated
and results are shown in Additional file 1: Table S6. We
found that, when this parameter ranged from 0.5 to 0.9,
the performance became stable and performed slightlybetter. Thus, the dependence of our method on this par-
ameter is slight, especially when the value of α is above
0.5. In addition, we observed that our algorithm was ro-
bust in 5000 random tests (Additional file 1: Table S7).
Comparison with the existing methods
We compared our method with some existing methods.
At present, several computational methods for miRNA-
disease association prediction have been proposed based
on different data sources, which makes it difficult
to carry out comparisons. Jiang et al. [5] used hyper-
geometric distribution to construct a miRNA functional
network for predicting miRNA-disease associations, and
achieved an AUC value of 75.80%. In our study, we used
a systematic approach to identify miRNA-disease asso-
ciations, which was based on functional connections
between miRNA targets and disease genes in PPI
network, and a global network measure distance meas-
ure realized by RWR algorithm was utilized. By apply-
ing this method to nine human cancers, we achieved
AUC values ranging from 71.3 to 91.3%. Chen et al.
proposed a computational method to infer miRNA-
disease associations based on random walk on the
miRNA-miRNA functional network [6]. Although this
method achieved a better AUC value of 86.17%, it was
not applicable to diseases which have no known re-
lated miRNAs. In addition, the miRNA-miRNA func-
tional similarity network they used was constructed
previously, which included 271 miRNAs and the giant
network component only contained 64 miRNAs. We
also compared our method with the hypergeometric
distribution method. A hypergeometric distribution
was performed to measure the association of a miRNA
and a disease by testing whether the overlap between
miRNA targets and disease genes was statistically sig-
nificant. The results showed that our strategy was
more advantageous than the hypergeometric distribu-
tion method (Additional file 1: Table S8).
Construction of a miRNA-disease network
We prioritized 499 miRNAs for each of the 269 dis-
eases according to p-values. At a p-value threshold of
0.05, we obtained a miRNA-disease network that in-
cluded 715 nodes (454 miRNAs and 261 diseases) and
2858 interactions (Figure 2; also see Additional file 2).
Squamous cell cancer and glioma cancer were ana-
lyzed as two examples (Table 1), and we found that
there were eight and six miRNAs in the top 10, re-
spectively. For instance, hsa-miR-183 was ranked at 1
in squamous cell cancer, which has been found to be
downregulated in head and neck squamous cell car-
cinoma by real-time PCR [37]. Hsa-miR-148a, which
was ranked at 1 in glioma, was recently determined to
be overexpressed in human glioblastoma multiforme
Figure 2 The constructed miRNA-disease network. The bipartite network was composed of miRNAs (triangles) and diseases (circles). A disease
is linked by miRNA if the p-value is less than 0.05. Disease nodes are colored according to disease class information from GAD; diseases are
classified into 18 categories. The size of a node is proportional to the degree of the node, whereas the thickness of an edge is proportional to
the p-value; the smaller the p-value the thicker the edge (A). The top 10 largest degree miRNAs in the miRNA-disease network (B). The top 10
largest degree diseases in the miRNA-disease network (C). The diseases associated with only one miRNA in the miRNA-disease network.
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results demonstrated that our method can effectively iden-
tify potential miRNA-disease associations, and that we
constructed a reliable miRNA-disease network.Global properties of miRNA regulation of disease genes
Next, we analyzed the global properties of miRNA regu-
lation of disease genes by the bipartite miRNA-disease
network. Firstly, we investigated the characteristics of
Table 1 Literature evidence for top 10 miRNAs of squamous cancer and glioma cancer
Squamous cancer Glioma cancer
miRNA Rank Literature validation PubMed ID miRNA Rank Literature validation PubMed ID
hsa-miR-183 1 Yes 16192569 hsa-miR-148a 1 Yes 19487573
hsa-miR-573 2 No - hsa-miR-148b 2 No -
hsa-miR-188-5p 3 Yes 16192569 hsa-miR-152 3 Yes 17363563
hsa-miR-34a 4 Yes 18381414 hsa-miR-205 4 No -
hsa-miR-9 5 Yes 18451220 hsa-miR-20b 5 No -
hsa-miR-23b 6 Yes 18381414 hsa-miR-589 6 No -
hsa-miR-518d-3p 7 No - hsa-miR-93 7 Yes 19487573
hsa-miR-148b 8 Yes 16192569 hsa-miR-222 8 Yes 19424584
hsa-miR-299-3p 9 Yes 18381414 hsa-miR-130a 9 Yes 16039986
hsa-miR-181d 10 Yes 19351747 hsa-miR-362-3p 10 Yes 19487573
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degree distribution. We found that the degree distribu-
tion for most miRNAs was low, and only a few miRNAs
played a global regulatory role in the regulation of a
large number of disorders (Additional file 1: Figure
S2A). For example, hsa-miR-590-5p exhibited the largest
degree and was recently found to be dysregulated in
many diseases [39-41]. The top 10 miRNAs that
exhibited the largest degree of distribution are shown in
Figure 2A. In the other hand, we observed that most of
the diseases were associated with only a small number of
miRNAs (Additional file 1: Figure S2B). Moreover, some
single, complex human diseases were related to numer-
ous miRNAs. Huntington's disease exhibited the largest
degree, which is associated with numerous miRNAs
such as hsa-miR-128 [42], hsa-miR-9* [43], and hsa-
miR-330 [44]. The top 10 diseases exhibiting the largest
degree of distribution are shown in Figure 2B.
Secondly, we investigated the correlation between miRNA
regulation and disease class. As shown in Additional file 1:
Figure S2C and Table 2, we found that neurological dis-
eases exhibited the largest average degree, whereas im-
mune diseases had the smallest average degree. This
result indicated that genes associated with neurologicalTable 2 The number of diseases and average degree in each









Cardiovascular 38 9.316diseases tended to be regulated by a higher number of
miRNAs. In contrast, genes involved in immune dis-
eases tended to be regulated by fewer miRNAs. This
phenomenon is shown in Figure 2C which also illus-
trates which diseases are associated with only one
miRNA. For example, Graves' and Addison's diseases
are correlated with only one miRNA and can be
regarded as miRNA-specific diseases, which is consist-
ent with the existing knowledge indicating that they are
pathway-specific diseases [14].
To evaluate the effect of the p-value threshold on con-
struction of the miRNA-disease network, another two
p-value thresholds, 0.1 and 0.01, were used to analyze
certain properties among the miRNA-disease networks.
Firstly, we analyzed the correlation of the miRNA degree
between each two of the three miRNA-disease networks.
As a result, they all significantly positively correlated
(see Additional file 1: Table S9). In the same manner, we
analyzed the correlation of the disease degree, which
yielded similar results (see Additional file 1: Table S9).
We also found that the top 10 largest degree of miRNAs
and diseases in these three miRNA-disease networks
were almost identical (see Additional file 1: Table S10).
Secondly, we investigated the correlation between miRNAdisease class
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networks. The results demonstrated that there was not
much change and that the neurological diseases always
exhibited the largest average degree (see Additional file 1:
Figure S2C and Figure S3).
MiRNA modules are associated with disease clusters
It has been reported that diseases within the same dis-
ease class tend to share a genetic origin and form local
functional clustering (modularity) [45]. To explore whe-
ther functional clustering existed in our miRNA-disease
bipartite network, the diseases in the miRNA-disease
network were assigned to 18 disease classes based on
GAD. We then used BD and BH measures to quantify
the modular properties in the network (for a detailed de-
scription, see Additional file 1). Both measures have
been used in a previous report to evaluate modularity
for bipartite networks [14]. If BD > BH, diseases belong-
ing to the disease class associated with the correspond-
ing miRNAs tend to exhibit clustering phenomena in
the network. For cases in which BD > 1 and BH < 1, the
diseases within the disease class associated with the cor-
responding miRNAs exhibit clear clustering tendencies
in the network.
We computed the BDs and BHs for the 18 disease
classes. As shown in Figure 3, all BDs > 1 and the aver-
age value of BDs for these disease classes was up to
7.411, whereas the average value of BHs was low (0.649).
For the neurological disease class, we found BD > 1 andFigure 3 Using BD and BH for evaluating the clustering
phenomenon for each disease class. If BD > BH, the diseases
belonging to the disease class associated with the corresponding
miRNAs tend to exhibit clustering phenomena in the network.
For cases in which BD > 1 and BH < 1, the diseases within the
disease class associated with the corresponding miRNAs exhibit clear
clustering tendencies in the network.BH < 1 (BD = 4.235 and BH = 0.902), suggesting that dis-
eases in this class associated with the corresponding
miRNAs display clear functional clustering phenomena.
The BDs and BHs of other disease classes all satisfied
BD > BH, indicating that diseases in these disease classes
associated with the corresponding miRNAs tended to
form functional clustering. Interestingly, the develop-
mental disease class (BD/BH = 7.412) and chemical de-
pendency disease class (BD/BH = 8.933) exhibited the
largest ratios of BD to BH. However, some disease clas-
ses exhibited smaller differences between BD and BH,
such as the other disease class that exhibited the
smallest ratio (2.074), which was potentially attributable
to the overlapping of disorders in other disease classes.
Similarly, we investigated whether the functional clus-
tering of a disease class existed when using different
p-value thresholds to construct the miRNA-disease
network. For each of the above three miRNA-disease
networks, we computed the BDs and BHs. As a result,
diseases in the same disease class associated with the
corresponding miRNAs displayed functional clustering
phenomena in all three networks (see Additional file 1:
Table S11), indicating that the results remained stable at
different p-value thresholds.
To further investigate the combinational regulatory ef-
fects of miRNAs on disease clusters in the miRNA-
disease network, we performed hierarchical clustering
on the bipartite network using Cluster3 software by the
city-block distance and complete linkage method (shown
by JavaTreeView imaging software; Figure 4). The hier-
archical clustering method is unsupervised and therefore
does not require disease class information for use in our
miRNA-disease network to identify miRNA-disease mo-
dules. As a result, we found that disorders within the
same disease class tended to cluster together (two exam-
ples are shown in Figure 4B). Most of the light pink
regions that are grouped together denote the immune
disease class and most of the dark blue, light blue, and
light yellow regions clustered together represent neuro-
logical, psychological, and chemical dependency disease
classes, respectively. We observed that not all of the
disorders in the same disease class gathered into one
cluster, and that the cluster included diseases from other
classes. This observation may be due to overlapping of
different disease classes in which one disease belonging
to a disease class is also classified into another disease
class. For example, schizophrenia belongs to the psycho-
logical disease class (GAD, Dec 15, 2008), but it is also
associated with the neurological system (Mesh).
Next, we identified certain co-regulated modules in
our miRNA-disease network (Figure 4C–E). As shown
in Figure 4C, hsa-miR-93, hsa-miR-20b, hsa-miR-20a,
and hsa-miR-106b may jointly regulate genes involved
in squamous cancer, glioma cancer, and reproductive
Figure 4 Hierarchical clustering of the miRNA-disease network. (A) Hierarchical clustering between 454 miRNAs and 261 diseases. Red cells
denote links between the corresponding miRNAs and diseases. Disease labels are colored according to disease class. (B) Zoom-in plot of disease
labels in Figure 4A. (C), (D), and (E) are zoom-in plots of corresponding purple circle regions in Figure 4A.
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previous reports showing that the expression of all of
these miRNAs is dysregulated in these diseases (for adetailed description, see Additional file 1: Table S12). In
addition, all four miRNAs belong to the miR-17 family,
and hsa-miR-93 and hsa-miR-106b are located in the
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17 family have been found to regulate cell cycle progres-
sion by targeting p21, and contribute to tumorigenesis
[46-48]. As shown in Figure 4D, all of the eight miRNAs
in this module co-regulated genes involved in the three
diseases in the same disease class (cardiovascular disease
class), indicating that these diseases might share similar
miRNA regulatory mechanisms. Recent findings have
provided some evidence in support of this hypothesis.
Wang et al. recently reported that loss of the miR-144/
miR-451 cluster limits ischemic preconditioning cardio-
protection by upregulation of Rac-1-mediated oxidative
stress signalling [49]. At the same time, hsa-miR-612 is
strongly downregulated (>log2 difference) in differentiated
human cardiomyocyte progenitor cells [50]. As illustrated
in Figure 4E, all of the eight miRNAs co-regulated genes
associated with the six diseases that belonged to the
neurological class and psychological class. Psychosis is a
psychological disease, but it was also classified as a
neurological disorder. We observed that the majority of
miRNAs in this module were dysregulated in neuro-
logical diseases. For example, hsa-miR-382, hsa-miR-31,
and hsa-miR-149 are downregulated in medulloblas-
toma [51], hsa-miR-378 is downregulated in Alzheimer’s
disease [52], and abnormal expression of hsa-miR-218
has been detected in samples from Parkinson’s disease
patients [53]. These co-regulated modules may enhance
our understanding of the combinational regulatory
mechanisms of miRNAs in complex human diseases.
Discussion
In this study, a computational framework was constructed
to identify miRNA-disease associations at the systematic
level. The associations were identified based on functional
link between miRNA targets and disease genes in PPI net-
work. To search for such functional link, we used a global
network distance measure, random walk analysis, which
can effectively capture the complex functional associations
between miRNA targets and disease genes.
Based on the identified miRNA-disease associations, we
constructed a miRNA-disease network to explore the rela-
tionships between miRNAs and diseases from a global
perspective. In addition, we analyzed the factors that affect
the number of diseases associated with miRNAs. We con-
sidered two factors for miRNA target genes and the ratios
of disease genes to miRNA targets. As a result, the num-
ber of diseases linked by miRNA negatively correlated
with the number of miRNA targets (r = −0.246, p = 0.638,
Pearson’s correlation; Additional file 1: Figure S4A). The
p value was not significant, suggesting that there may be
no relationship between the number of miRNA targets
and the number of associated diseases. We found that the
number of diseases linked by miRNA positively correlated
with the ratio of disease genes to miRNA targets(r = 0.884, p = 0.047; Additional file 1: Figure S4B). This
result indicated that the more disease genes targeted by a
miRNA, the higher the probability that the miRNA is as-
sociated with a greater number of diseases.
By analyzing the miRNA-disease bipartite network,
we found that diseases in the same disease class
tended to cluster together. The hierarchical clustering
in this network demonstrated that certain miRNAs
combinationally regulated genes involved in a certain
type of disease. For future studies, our method can be
extended to other kinds of functional modules, such
'as pathway, Gene Ontology, or integrated functional
modules, which contain different functional informa-
tion. This method may be more comprehensive for
dissection of the characteristics of miRNA regulation
of genes associated with human diseases. Although the
results might be affected by different miRNA targets
and PPI networks, to make the results more reliable,
we collected miRNA targets from seven commonly
used miRNA target databases by extracting those with
regulatory associations between miRNAs and targets,
which appeared in at least three databases. Consider-
ing that HPRD included the maximum number of PPIs
of any of the publicly available literature-derived data-
bases for human PPIs [54] and the annotations it
contained were based on experimental evidence, we
chose to compile PPI data from this database. We also
used human signaling networks to confirm our ap-
proach. With improvements in the quantity and qual-
ity of data sources, the miRNA-disease network will be
more accurate and comprehensive. In summary, the
methods proposed in our study could potentially play
an important role in miRNA research and serve as a
powerful tool for further elucidation of the molecular
basis of human pathologies.
Conclusions
In conclusion, by focusing on the functional connectivity
between miRNA targets and disease genes in PPI
network, we developed a computational framework to
identify disease-related miRNAs using a global network
distance measure realized by RWR algorithm. We fur-
ther constructed a miRNA-disease network to systemat-
ically analyze the global properties of miRNA regulation
of disease genes. This will considerably deepen our un-
derstanding of the molecular mechanisms of diseases at
the post-transcriptional level.
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